Cargando…

A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis

OBJECTIVE: Inhibition of dihydroorotate dehydrogenase suppresses magnetic resonance imaging brain lesions and disease activity in multiple sclerosis but has limiting tolerability. We assessed the safety and efficacy of vidofludimus calcium, a novel, selective dihydroorotate dehydrogenase inhibitor,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fox, Robert J., Wiendl, Heinz, Wolf, Christian, De Stefano, Nicola, Sellner, Johann, Gryb, Viktoriia, Rejdak, Konrad, Bozhinov, Plamen Stoyanov, Tomakh, Nataliya, Skrypchenko, Iryna, Muehler, Andreas R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268865/ https://www.ncbi.nlm.nih.gov/pubmed/35698927 http://dx.doi.org/10.1002/acn3.51574

Ejemplares similares

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
por: Muehler, Andreas, et al.
Publicado: (2019)

Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
por: Muehler, Andreas, et al.
Publicado: (2020)

Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum
por: Ross, Leila Saxby, et al.
Publicado: (2018)

Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation
por: Saunthararajah, Yogen
Publicado: (2020)

Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase
por: Xu, Yechun, et al.
Publicado: (2020)

Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay
por: Schölermann, Beate, et al.
Publicado: (2022)

Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
por: Vehreschild, Maria J. G. T., et al.
Publicado: (2022)

A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis
por: Carey, Elizabeth J., et al.
Publicado: (2022)

Fluorescence assay of dihydroorotate dehydrogenase that may become a cancer biomarker
por: Yin, Sheng, et al.
Publicado: (2017)

Isoxazolopyrimidine-Based Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity
por: Kokkonda, Sreekanth, et al.
Publicado: (2018)

Structural insights into inhibition of the drug target dihydroorotate dehydrogenase by bacterial hydroxyalkylquinolines
por: Horwitz, Samantha M., et al.
Publicado: (2022)

Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
por: Houshmand, Mohammad, et al.
Publicado: (2022)

Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition
por: Arnould, Stéphanie, et al.
Publicado: (2017)

Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P. falciparum Dihydroorotate Dehydrogenase
por: Maetani, Micah, et al.
Publicado: (2017)

Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma
por: Yu, Yajie, et al.
Publicado: (2021)

Combination of consensus and ensemble docking strategies for the discovery of human dihydroorotate dehydrogenase inhibitors
por: Chilingaryan, Garri, et al.
Publicado: (2021)

Repurposed dihydroorotate dehydrogenase inhibitors with efficacy against drug-resistant Acinetobacter baumannii
por: Russo, Thomas A., et al.
Publicado: (2022)

Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors
por: Deng, Xiaoyi, et al.
Publicado: (2014)

Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase
por: Costeira-Paulo, Joana, et al.
Publicado: (2018)

Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells
por: Wu, Dang, et al.
Publicado: (2018)

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Structural and Biochemical Features of Eimeria tenella Dihydroorotate Dehydrogenase, a Potential Drug Target
por: Sato, Dan, et al.
Publicado: (2020)

Molecular docking analysis of Plasmodium falciparum dihydroorotate dehydrogenase towards the design of effective inhibitors
por: Owoloye, Afolabi, et al.
Publicado: (2020)

Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study
por: Galati, Salvatore, et al.
Publicado: (2022)

The target site of the novel fungicide quinofumelin, Pyricularia oryzae class II dihydroorotate dehydrogenase
por: Higashimura, Norikazu, et al.
Publicado: (2022)

Identification of a dihydroorotate dehydrogenase inhibitor that inhibits cancer cell growth by proteomic profiling
por: KAWATANI, MAKOTO, et al.
Publicado: (2023)

Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD
por: Zhu, Yanlin, et al.
Publicado: (2020)

The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III
por: Khutornenko, A. A., et al.
Publicado: (2014)

Crystal structures of FMN‐bound and FMN‐free forms of dihydroorotate dehydrogenase from Trypanosoma brucei
por: Kubota, Tomomi, et al.
Publicado: (2018)

Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase
por: Dorasamy, Mathura Subangari, et al.
Publicado: (2017)

Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro
por: Kim, Yu-Jin, et al.
Publicado: (2020)

Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia
por: Branstrom, Arthur, et al.
Publicado: (2022)

Novel fungicide quinofumelin shows selectivity for fungal dihydroorotate dehydrogenase over the corresponding human enzyme
por: Higashimura, Norikazu, et al.
Publicado: (2023)

3D-QSAR Studies on a Series of Dihydroorotate Dehydrogenase Inhibitors: Analogues of the Active Metabolite of Leflunomide
por: Li, Shun-Lai, et al.
Publicado: (2011)

Babesia bovis Dihydroorotate Dehydrogenase (BboDHODH) is a Novel Molecular Target of Drug for Bovine Babesiosis
por: KAMYINGKIRD, Ketsarin, et al.
Publicado: (2013)

Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum
por: Dickerman, Benjamin K., et al.
Publicado: (2016)

Selective Cytotoxicity of Dihydroorotate Dehydrogenase Inhibitors to Human Cancer Cells Under Hypoxia and Nutrient-Deprived Conditions
por: Miyazaki, Yukiko, et al.
Publicado: (2018)

Structural Optimization and Structure–Activity Relationship of 4-Thiazolidinone Derivatives as Novel Inhibitors of Human Dihydroorotate Dehydrogenase
por: Zeng, Fanxun, et al.
Publicado: (2019)

Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology
por: Ladds, Marcus J. G.W., et al.
Publicado: (2021)

Class-II dihydroorotate dehydrogenases from three phylogenetically distant fungi support anaerobic pyrimidine biosynthesis
por: Bouwknegt, Jonna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eoq8pdo5lju36nsl6ck5lsm4m7